August, 06 2026 Thursday 08:49 Hrs
Last update 11-9-2025
  • SENSEX :   78,581.00

  • Commodity broking firm in India152.05( 0.19%) 05-Aug-2026
Positive
Sensex 78581 152.05  (0.19) 05-Aug-2026
Previous Day Close 78428.95
Today's High/Low
High Low
  •  
  •  
79055.38 78285.74

Company News Details

Lupin Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500257
INE326A01037
659.0470742
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
LUPIN
18.89
109095.68
EPS(TTM)
Face Value()
Div & Yield %
126.28
2
0.75
 

lupin ltd
Lupin grants exclusive rights to Kaveri Therapeutics Inc. for advancing two oncology programs
Jul 21,2026

Lupin announced the strategic spin-out of two oncology programs – LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary, Lupin Inc., into Kaveri Therapeutics Inc. (Kaveri), a U.S. based clinical-stage oncology company. Kaveri will advance these programs through global clinical trials.

Under the terms of the agreement, Lupin Inc. will have a significant equity stake in Kaveri, provide seed funding, and grant them exclusive rights to the programs.

Kaveri will operate as an independent entity under the leadership of Chief Executive Officer Kristi Jones, a seasoned biopharmaceutical leader with a strong track record of building and advancing innovative companies, and Chief Medical Officer Dr. Robert Pierce, who brings deep clinical expertise and will lead the company's clinical development strategy.

Kaveri will seek to raise additional capital to fund its clinical development efforts. Notably, both programs have demonstrated encouraging clinical progress, with LNP7457 (PRMT5) and LNP8701 (SOS1) each reporting positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively.

Top

Attention Investor:

Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.